ArticleInternal medicine (Tokyo, Japan)2026
Evaluation of the Short-term Effect of Pemafibrate on Liver Fibrosis Biomarkers Stratified by FIB-4 Index in Patients with Type 2 Diabetes Mellitus and Hypertriglyceridemia.
Article in Internal medicine (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective This study aimed to investigate the short-term effects of pemafibrate (PEMA) on the Fibrosis-4 index (FIB-4) and Aspartate Aminotransferase to Platelet Ratio Index (APRI) across three subgroups stratified according to FIB-4 for assessing the risk of liver fibrosis in patients with type 2 diabetes (T2D) and hypertriglyceridemia. Methods A total of 114 patients were stratified into three subgroups based on their FIB-4 score at the initiation of PEMA, following the FIB-4 classification: Group 1 (G1) (FIB-4<1.30, n=46), Group 2 (G2) (FIB-4 1.30 to <2.67, n=56), and Group 3 (G3) (FIB-4 ≥2.67, n=12). We evaluated the changes in FIB-4 and APRI three months after the initiation of PEMA in each subgroup. Subsequently, we compared the changes (Δ) in FIB-4 and APRI scores across the three subgroups. Additionally, we investigated the baseline parameters and changes in these parameters correlated with ΔFIB-4. Results The FIB-4 index exhibited a significant increase in G1 (p=0.003) but decrease in G3 (p=0.041). The APRI showed a significant reduction in both G2 (p<0.001) and G3 (p=0.034). ΔFIB-4 in G3 was significantly greater than that observed in G1 (p<0.001) and G2 (p=0.026), whereas ΔAPRI in G3 was significantly higher than that in G1 (p=0.002). ΔFIB-4 was inversely correlated with baseline FIB-4 and positively correlated with Δγ-glutamyl transpeptidase. Conclusion The short-term effect of PEMA on liver fibrosis markers was more pronounced in patients with T2D and hypertriglyceridemia who exhibited elevated baseline FIB-4 values.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.